Novartis, Amgen, and Bristol-Myers Squibb Report Sales Up in Third Quarter - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis, Amgen, and Bristol-Myers Squibb Report Sales Up in Third Quarter


Pharmaceutical industry leaders Novartis, Amgen, and Bristol-Myers Squibb—among others—released third-quarter 2013 results showing increased sales.  

Novartis reported group net sales up 4%, or 6% on a constant-currency basis, over the third-quarter of 2012 to $14.3 billion in the third quarter of 2013, the company said in a press release. The company’s underlying business, excluding the impact of patent expiries, demonstrated strong growth, with underlying net sales up 10% on a constant-currency basis in the third quarter.  Although all divisions contributed to growth, the company’s growth products were particularly strong with 17% growth in the quarter. Novartis’ sales in emerging markets showed 9% growth on a constant-currency basis for the quarter, led by China and Russia.  

Amgen reported 11% product sales growth in the third-quarter of 2013, the company said in a press release. Total revenues for the third quarter were $4.7 billion. In the third quarter, Amgen closed on its acquisition of Onyx Pharmaceuticals and began operation of the Amgen–Astellas alliance in Japan and the Betta Pharma joint venture in China. 

Bristol-Myers Squibb’s net sales were up 9% to $4.1 billion in the third quarter, the company announced in a press release. Leading products with double-digit growth included Yervoy (ipilimumab), Onglyza(saxagliptin)/Kombiglyze (saxagliptin and metformin hydrochloride), Sprycel (dasatinib), and Orencia (abatacept).

Sources:
Novartis

Amgen

Bristol-Myers Squibb

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here